Simplifying Global Compliance
Risk-Based Assessments Urged For Therapeutic Protein Products
Washington Drug Letter
Manufacturers and clinical investigators developing therapeutic protein products, such as monoclonal antibody cancer drugs, are urged to adopt risk-based assessments of patient immune responses that could impair drug safety and efficacy, draft FDA guidance states.
To View This Article:
Buy This Article Now
Copyright ©2018. All Rights Reserved.
Design, CMS, Hosting & Web Development :: ePublishing